Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders

CNS Drugs

Volumn 20, Issue 3, 2006, Pages 173-185

  Marenco, Stefano ^a   Weinberger, Daniel R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; 7 CHLORO 3,4 DIHYDRO 3 METHYL 2H 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; AMPA RECEPTOR ANTAGONIST; ANIRACETAM; BENZAMIDE DERIVATIVE; BENZTHIAZIDE; CX 546; CX 614; CX 717; CYCLOTHIAZIDE; DIAZOXIDE; FARAPAMPATOR; LY 392098; LY 404187; LY 451395; LY 451646; LY 503430; ORG 24448; PYRROLIDINE DERIVATIVE; S 18986; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG POTENCY; EUROPE; FRAGILE X SYNDROME; HALF LIFE TIME; HUMAN; MEDICAL LITERATURE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; UNITED STATES;

ANIMALS; BRAIN DISEASES; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; MENTAL DISORDERS; NOOTROPIC AGENTS; RECEPTORS, AMPA;

EID: 33644927557     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620030-00001     Document Type: Review

References (101)

1. Xia YF, Kessler M, Arai AC. Positive alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) receptor modulators have different impact on synaptic transmission in the thalamus and hippocampus. J Pharmacol Exp Ther 2005; 313 (1): 277-85
2. Black MD. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits: a review of preclinical data. Psychopharmacology (Berl) 2005; 179 (1): 154-63
3. Ito I, Tanabe S, Kohda A, et al. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J Physiol 1990; 424: 533-43
4. Cumin R, Bandle EF, Gamzu E, et al. Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology (Berl) 1982; 78 (2): 104-11
5. Ma YX, Yu ZY, Jin YS, et al. Double-blind trail of aniracetam on cognitive impairment in 622 cases. Naunyn Schmiedebergs Arch Pharmacol 1998; 358 (1): R480
6. Nagasaka T, Togashi S, Amino A, et al. Aniracetam for treatment of patients with progressive supranuclear palsy. Eur Neurol 1997; 37 (3): 195-8
7. Senin U, Parnetti L, Cucinotta D, et al. Clinical-experience with aniracetam in the treatment of senile dementia of the Alzheimer-type and related disorders. Drug Investigation 1993; 5: 96-105
8. Mizuki Y. Effects of aniracetam, a nootropic drug, on clinical symptoms and EEGs in senile dementia. Electroencephalogr Clin Neurophysiol 1988; 70 (5): P113
9. Vincent G, Verderese A, Gamzu E. The effects of aniracetam (Ro 13-5057) on the enhancement and protection of memory. Ann N Y Acad Sci 1985; 444: 489-91
10. Lahdes A, Molsa P, Portin R, et al. Aniracetam in treatment of senile dementia of the Alzheimer type-A neuropsychological study. J Clin Exp Neuropsychol 1985; 7 (2): 151
11. Bertolino M, Baraldi M, Parenti C, et al. Modulation of AMPA/kainate receptors by analogs of diazoxide and cyclothiazide in thin slices of rat hippocampus. Recept. Channels 1993; 1 (4): 267-78
12. Phillips D, Sonnenberg J, Arai AC, et al. 5′-alkyl- benzothiadiazides: a new subgroup of AMPA receptor modulators with improved affinity. Bioorg Med Chem 2002; 10 (5): 1229-48
13. Pirotte B, Podona T, Diouf O, et al. 4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors: design, synthesis, pharmacology, and structure-activity relationships. J Med Chem 1998; 41 (16): 2946-59
14. Arai AC, Xia YF, Kessler M, et al. Effects of 5′- alkylbenzothiadiazides on (R,S)-alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) receptor biophysics and synaptic responses. Mol Pharmacol 2002; 62 (3): 566-77
15. Ornstein PL, Zimmerman DM, Arnold MB, et al. Biarylpropylsulfonamides as novel, potent potentiators of 2-amino-3- (5-methyl-3-hydroxyisoxazol-4-yl)- propanoic acid (AMPA) receptors. J Med Chem 2000; 43 (23): 4354-8
16. Baumbarger P, Muhlhauser M, Yang CR, et al. LY392098, a novel AMPA receptor potentiator: electrophysiological studies in prefrontal cortical neurons. Neuropharmacology 2001; 40 (8): 992-1002
17. Gates M, Ogden A, Bleakman D. Pharmacological effects of AMPA receptor potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in vitro. Neuropharmacology 2001; 40 (8): 984-91
18. Lawrence JJ, Brenowitz S, Trussell LO. The mechanism of action of aniracetam at synaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors: indirect and direct effects on desensitization. Mol Pharmacol 2003; 64 (2): 269-78
19. Arai AC, Xia YF, Rogers G, et al. Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action. J Pharmacol Exp Ther 2002; 303 (3): 1075-85
20. Arai A, Kessler M, Rogers G, et al. Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus. J Pharmacol Exp Ther 1996; 278 (2): 627-38
21. Porrino LJ, Daunais JB, Rogers GA, et al. Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. PLoS Biol 2005; 3 (9): e299
22. Jordan GR, McCulloch J, Shahid M, et al. Regionally selective and dose-dependent effects of the ampakines Org 26576 and Org 24448 on local cerebral glucose utilisation in the mouse as assessed by C-14-2-deoxyglucose autoradiography. Neuropharmacology 2005; 49 (2): 254-64
23. Lockhart B, Iop F, Closier M, et al. (S)-2,3-dihydro- 3,4 cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide: (S18986-1) a positive modulator of AMPA receptors enhances (S)-AMPA-mediated H-3 noradrenaline release from rat hippocampal and frontal cortex slices. Eur J Pharmacol 2000; 401 (2): 145-53
24. Yamada KA, Tang CM. Benzothiadiazides inhibit rapid glutamate receptor desensitization and enhance glutamatergic synaptic currents. J Neurosci 1993; 13 (9): 3904-15
25. Yamada KA, Rothman SM. Diazoxide blocks glutamate desensitization and prolongs excitatory postsynaptic currents in rat hippocampal neurons. J Physiol 1992; 458: 409-23
26. Partin KM, Fleck MW, Mayer ML. AMPA receptor flip/flop mutants affecting deactivation, desensitization, and modulation by cyclothiazide, aniracetam, and thiocyanate. J Neurosci 1996; 16 (21): 6634-47
27. Arai A, Lynch G. AMPA receptor desensitization modulates synaptic responses induced by repetitive afferent stimulation in hippocampal slices. Brain Res 1998; 799 (2): 235-42
28. Yamada KA. Modulating excitatory synaptic neurotransmission: potential treatment for neurological disease? Neurobiol Dis 1998; 5 (2): 67-80
29. Sekiguchi M, Nishikawa K, Aoki S, et al. A desensitization-selective potentiator of AMPA-type glutamate receptors. Br J Pharmacol 2002; 136 (7): 1033-41
30. Quirk JC, Nisenbaum ES. LY404187: a novel positive allosteric modulator of AMPA receptors. CNS Drug Rev 2002; 8 (3): 255-82
31. Toublanc N, Chalon S, Pereira A, et al. Single dose safety, tolerance, and pharmacokinetics of LY451395, an AMPA potentiator, in young healthy male subjects. Eur Neuropsychopharmacol 2002; 12: S422
32. O'Neill MJ, Murray TK, Clay MP, et al. LY503430: Pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease. CNS Drug Rev 2005; 11 (1): 77-96
33. Lynch G. AMPA receptor modulators as cognitive enhancers. Curr Opin Pharmacol 2004; 4 (1): 4-11
34. Partin KM, Patneau DK, Mayer ML. Cyclothiazide differentially modulates desensitization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor splice variants. Mol Pharmacol 1994; 46 (1): 129-38
35. Nagarajan N, Quast C, Boxall AR, et al. Mechanism and impact of allosteric AMPA receptor modulation by the Ampakine (TM) CX546. Neuropharmacology 2001; 41 (6): 650-63
36. Arai AC, Xia YF, Suzuki E. Modulation of AMPA receptor kinetics differentially influences synaptic plasticity in the hippocampus. Neuroscience 2004; 123 (4): 1011-24
37. Arai A, Lynch G. Factors regulating the magnitude of long-term potentiation induced by theta pattern stimulation. Brain Res 1992; 598 (1-2): 173-84
38. Staubli U, Perez Y, Xu FB, et al. Centrally active modulators of glutamate receptors facilitate the induction of long-term potentiation in-vivo. Proc Natl Acad Sci U S A 1994; 91 (23): 11158-62
39. Cooke SF, Bliss TV. Long-term potentiation and cognitive drug discovery. Curr Opin Investig Drugs 2005; 6 (1): 25-34
40. Leever JD, Clark S, Weeks AM, et al. Identification of a site in GluR1 and GluR2 that is important for modulation of deactivation and desensitization. Mol Pharmacol 2003; 64 (1): 5-10
41. Giovannini MG, Rakovska A, Della Corte L, et al. Activation of non-NMDA receptors stimulates acetylcholine and GABA release from dorsal hippocampus: a microdialysis study in the rat. Neurosci Lett 1998; 243 (1-3): 152-6
42. Maione S, Biggs CS, Rossi F, et al. alpha-Amino-3-hydroxy-5-methyl-4- isoxazolepropionate receptors modulate dopamine release in rat hippocampus and striatum. Neurosci Lett 1995; 193 (3): 181-4
43. Tao R, Ma Z, Auerbach SB. Influence of AMPA/kainate receptors on extracellular 5-hydroxytryptamine in rat midbrain raphe and forebrain. Br J Pharmacol 1997; 121 (8): 1707-15
44. Hampson RE, Rogers G, Lynch G, et al. Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. J Neurosci 1998; 18 (7): 2748-63
45. Hampson RE, Rogers G, Lynch G, et al. Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to- sample performance. J Neurosci 1998; 18 (7): 2740-7
46. Martin JR, Cumin R, Aschwanden W, et al. Aniracetam improves radial maze performance in rats. Neuroreport 1992; 3 (1): 81-3
47. Granger R, Staubli U, Davis M, et al. A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task. Synapse 1993; 15 (4): 326-9
48. Granger R, Deadwyler S, Davis M, et al. Facilitation of glutamate receptors reverses an age-associated memory impairment in rats. Synapse 1996; 22 (4): 332-7
49. Staubli U, Rogers G, Lynch G. Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci U S A 1994; 91 (2): 777-81
50. Davis CM, Moskovitz B, Nguyen MA, et al. A profile of the behavioral changes produced by facilitation of AMPA type glutamate receptors. Psychopharmacology 1997; 133 (2): 161-7
51. Zivkovic I, Thompson DM, Bertolino M, et al. 7-chloro-3-methyl-3-4- dihydro-2h-1,2,4 benzothiadiazine s,s-dioxide (idra-21) - a benzothiadiazine derivative that enhances cognition by attenuating dl-alpha-amino-2,3-dihydro-5- methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J Pharmacol Exp Ther 1995; 272 (1): 300-9
52. Lebrun C, Pilliere E, Lestage P. Effects of S 18986-1, a novel cognitive enhancer, on memory performances in an object recognition task in rats. Eur J Pharmacol 2000; 401 (2): 205-12
53. Larson J, Lieu T, Petchpradub V, et al. Facilitation of olfactory learning by a modulator of AMPA receptors. J Neurosci 1995; 15 (12): 8023-30
54. Rogan MT, Staubli UV, LeDoux JE. AMPA receptor facilitation accelerates fear learning without altering the level of conditioned fear acquired. J Neurosci 1997; 17 (15): 5928-35
55. Shors TJ, Servatius RJ, Thompson RF, et al. Enhanced glutamatergic neurotransmission facilitates classical conditioning in the freely moving rat. Neurosci Lett 1995; 186 (2-3): 153-6
56. Davis M. The role of the amygdala in conditioned fear. In: The amygdala: neurobiological aspects of emotion, memory and mental dysfunction. Aggleton JP, ed. New York: Wiley & Sons, 1992: 255-306
57. Pontecorvo MJ, Evans HL. Effects of aniracetam on delayed matching-to-sample performance of monkeys and pigeons. Pharmacol Biochem Behav 1985; 22 (5): 745-52
58. Thompson DM, Guidotti A, Dibella M, et al. 7-chloro-3-methyl-3,4-dihydro- 2h-1,2,4-benzothiadiazine s,s-dioxide (idra-21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys. Proc Natl Acad Sci U S A 1995; 92 (17): 7667-71
59. Zafra F, Hengerer B, Leibrock J, et al. Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. EMBO J 1990; 9 (11): 3545-50
60. Hayashi T, Umemori H, Mishina M, et al. The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn. Nature 1999; 397 (6714): 72-6
61. Lauterborn JC, Truong GS, Baudry M, et al. Chronic elevation of brain-derived neurotrophic factor by ampakines. J Pharmacol Exp Ther 2003; 307 (1): 297-305
62. Lauterborn JC, Lynch G, Vanderklish P, et al. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci 2000; 20 (1): 8-21
63. Legutko B, Li X, Skolnick P. Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator. Neuropharmacology 2001; 40 (8): 1019-27
64. Mackowiak M, O'Neill MJ, Hicks CA, et al. An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study. Neuropharmacology 2002; 43 (1): 1-10
65. Dicou E, Rangon CM, Guimiot F, et al. Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain. Brain Res 2003; 970 (1-2): 221-5
66. Bai F, Bergeron M, Nelson DL. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology 2003; 44 (8): 1013-21
67. Duman RS. Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 1998; 44 (5): 324-35
68. Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2004; 27 (10): 589-94
69. Li X, Tizzano JP, Griffey K, et al. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001; 40 (8): 1028-33
70. Li X, Witkin JM, Need AB, et al. Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cell Mol Neurobiol 2003; 23 (3): 419-30
71. Bai F, Li X, Clay M, et al. Intra- and interstrain differences in models of "behavioral despair". Pharmacol Biochem Behav 2001; 70 (2-3): 187-92
72. Knapp RJ, Goldenberg R, Shuck C, et al. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol 2002; 440 (1): 27-35
73. Alt A, Witkin JM, Bleakman D. AMPA receptor potentiators as novel antidepressants. Curr Pharm Des 2005; 11 (12): 1511-27
74. Hariri AR, Goldberg TE, Mattay VS, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003; 23 (17): 6690-4
75. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112 (2): 257-69
76. O'Neill MJ, Murray TK, Whalley K, et al. Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease. Eur J Pharmacol 2004; 486 (2): 163-74
77. Murray TK, Whalley K, Robinson CS, et al. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J Pharmacol Exp Ther 2003; 306 (2): 752-62
78. Murray TK, Whalley K, Ward MA, et al. The novel AMPA receptor potentiator, LY404187, is neurotrophic in a nigral 6-hydroxydopamine model of Parkinson's disease. Mov Disord 2002; 17: S29
79. Siegel GJ, Chauhan NB. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Brain Res Rev 2000; 33 (2-3): 199-227
80. Bodner SM, Berrettini W, van Deerlin V, et al. Genetic variation in the brain derived neurotrophic factor gene in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2005; 134 (1): 1-5
81. Combarros O, Infante J, Llorca J, et al. Polymorphism at codon 66 of the brain-derived neurotrophic factor gene is not associated with sporadic Alzheimer's disease. Dement Geriatr Cogn Disord 2004; 18 (1): 55-8
82. Bagnoli S, Nacmias B, Tedde A, et al. Brain-derived neurotrophic factor genetic variants are not susceptibility factors to Alzheimer's disease in Italy. Ann Neurol 2004; 55 (3): 447-8
83. Tsai SJ, Hong CJ, Liu HC, et al. Association analysis of brain-derived neurotrophic factor Val66Met polymorphisms with Alzheimer's disease and age of onset. Neuropsychobiology 2004; 49 (1): 10-2
84. Riemenschneider M, Schwarz S, Wagenpfeil S, et al. A polymorphism of the brain-derived neurotrophic factor (BDNF) is associated with Alzheimer's disease in patients lacking the Apolipoprotein E epsilon4 allele. Mol Psychiatry 2002; 7 (7): 782-5
85. Ventriglia M, Bocchio Chiavetto L, Benussi L, et al. Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease. Mol Psychiatry 2002; 7 (2): 136-7
86. Kunugi H, Ueki A, Otsuka M, et al. A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer's disease. Mol Psychiatry 2001; 6 (1): 83-6
87. Larson J, Quach CN, LeDuc BQ, et al. Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats. Brain Res 1996; 738 (2): 353-6
88. Hess US, Whalen SP, Sandoval LM, et al. Ampakines reduce methamphetamine-driven rotation and activate neocortex in a regionally selective fashion. Neuroscience 2003; 121 (2): 509-21
89. Johnson SA, Luu NT, Herbst TA, et al. Synergistic interactions between ampakines and antipsychotic drugs. J Pharmacol Exp Ther 1999; 289 (1): 392-7
90. Porrino LJ, Daunais JB, Rogers GA, et al. Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. PLoS Biol 2005; 3 (9): 1639-52
91. Jones N, O'Neill MJ, Tricklebank M, et al. Examining the neural targets of the AMPA receptor potentiator LY404187 in the rat brain using pharmacological magnetic resonance imaging. Psychopharmacology 2005; 180 (4): 743-51
92. Fowler JH, Whalley K, Murray T, et al. The AMPA receptor potentiator LY404187 increases cerebral glucose utilization and c-fos expression in the rat. J Cereb Blood Flow Metab 2004; 24 (10): 1098-109
93. Pellerin L, Magistretti PJ. Ampakine CX546 bolsters energetic response of astrocytes: a novel target for cognitive-enhancing drugs acting as alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators. J Neurochem 2005; 92 (3): 668-77
94. Skolnick P, Legutko B, Li X, et al. Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol Res 2001; 43 (5): 411-23
95. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61 (11): 1136-44
96. Lynch G, Granger R, Ambros-Ingerson J, et al. Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp Neurol 1997; 145 (1): 89-92
97. Ingvar M, Ambros-Ingerson J, Davis M, et al. Enhancement by an ampakine of memory encoding in humans. Exp Neurol 1997; 146 (2): 553-9
98. Morris MJ, Chase TN, Johnson SA. Glutamatergic therapy for Alzheimer's disease: safety, tolerability and preliminary efficacy of CX516. Neurobiol Aging 2002; 23 (1): S555
99. Li J, Pelletier MR, Perez Velazquez JL, et al. Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Mol Cell Neurosci 2002; 19 (2): 138-51
100. Goff DC, Leahy L, Berman I, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001; 21 (5): 484-7
101. Marenco S, Egan MF, Goldberg TE, et al. Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophr Res 2002; 57 (2-3): 221-6